viewCellmid Limited

Cellmid's Maria Halasz buys shares on market

Maria Halasz has increased her shareholding through buying on market.

Cellmid shares are up 15% in 2017 trading at $0.03

Cellmid (ASX:CDY) has had its managing director and CEO, Maria Halasz, purchase 400,000 shares on market recently.

This takes Halasz’s Total direct and indirect holding to 27.3 million shares.

Total consideration for the 400,000 shares purchased amounted to $11,600 for an average price of $0.029.

Cellmid has two business segments, consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.

Cellmid recorded a 79% increase in December quarter hair loss product sales compared with the prior December quarter and will enter 2017 with a healthy $5.3 million in cash.

Quick facts: Cellmid Limited

Price: 0.1 AUD

Market: ASX
Market Cap: $12.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...


Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read